Results 261 to 270 of about 2,772,421 (294)

Management of Epilepsy in Drug-Resistant Patients

CNS Spectrums, 2010
Epilepsy affects > 2 million people in the United States, making it one of the most common neurobiological conditions. Typically, epilepsy is treated with one of several available antiepileptic drugs and patients are able to experience freedom from seizures with minimal side effects.
Brien J, Smith, Andrew J, Cole
openaire   +2 more sources

Connectome biomarkers of drug‐resistant epilepsy

Epilepsia, 2020
AbstractDrug‐resistant epilepsy (DRE) considerably affects patient health, cognition, and well‐being, and disproportionally contributes to the overall burden of epilepsy. The most common DRE syndromes are temporal lobe epilepsy related to mesiotemporal sclerosis and extratemporal epilepsy related to cortical malformations.
Sara Larivière, Andrea Bernasconi, Neda Bernasconi, Boris C. Bernhardt   +3 more
openaire   +2 more sources

Identification and Treatment of Drug-Resistant Epilepsy

Continuum, 2019
Drug-resistant epilepsy is a potentially life-threatening condition affecting one-third of people living with epilepsy. Despite existing evidence of improved outcomes in patients who received surgical treatment compared to continued medical treatment, epilepsy surgery remains underused in patients with drug-resistant epilepsy.
Ji Yeoun, Yoo, Fedor, Panov
openaire   +2 more sources

Neuromodulation for the Treatment of Drug-Resistant Epilepsy

2014
Surgical neuromodulation for epilepsy refers to procedures involving the electrical stimulation of cortical, diencephalic, cerebellar and peripheral targets (such as the vagus nerve). Stereotactic radiosurgery also provides a neuromodulatory approach, affecting the discharging behavior of epileptic neurons in absence of evident target necrosis ...
Romanelli, Pantaleo, Conti, Alfredo
openaire   +3 more sources

Drug resistance in epilepsy: human epilepsy.

Novartis Foundation symposium, 2002
The basis of drug resistance in human epilepsy is not understood. Parallels with resistance in cancer suggest that drug resistance proteins may have a role. To examine this possibility, we have studied human brain tissue containing pathologies capable of causing refractory epilepsy.
S M, Sisodiya, W R, Lint, B N, Harding, M V, Squier, M, Thom   +4 more
openaire   +1 more source

Neuromodulation in pediatric drug-resistant epilepsy

Epilepsy & Behavior
This is a summary of the three commercially available neuromodulation devices for refractory epilepsy, highlighting their use in children. The article offers a high-level review of the proposed mechanisms of vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation, the pivotal trials leading to their approval for use in the ...
Ann, Hyslop, Marytery, Fajardo
openaire   +2 more sources

Resective Epilepsy Surgery for Drug-Resistant Focal Epilepsy

JAMA, 2015
Epilepsy surgery is indicated for patients with focal seizures who do not respond to appropriate antiepileptic drug therapy consisting of 2 or more medications.To review resective surgery outcomes for focal epilepsy, to identify which patients benefit the most, and to discuss why epilepsy surgery may not be universally accepted.Medline and Cochrane ...
Barbara C, Jobst, Gregory D, Cascino
openaire   +2 more sources

Surgical treatment of drug-resistant epilepsy

Burdenko's Journal of Neurosurgery
Background. Surgical treatment is possible for drug-resistant epilepsy. Localization of epileptogenic zone in temporal lobe or outside it influences the effectiveness of surgical treatment. Objective. To evaluate the effectiveness of surgical treatment of drug-resistant epilepsy. Material and methods.
A.A. Zuev, N.V. Pedyash, N.P. Utyashev, N.O. Ivin, A.A. Utyasheva, E.A. Gordeeva   +5 more
openaire   +2 more sources

Update on Cannabidiol in Drug-Resistant Epilepsy

Indian Journal of Pediatrics
Cannabidiol (CBD) has arisen as a promising therapeutic option for children with drug-resistant epilepsy (DRE). CBD has received regulatory nod from different regulatory authorities in the United States, Europe, and India for children with DRE particularly, Dravet syndrome (DS), Lennox Gastaut syndrome (LGS), and Tuberous sclerosis complex (TSC ...
Akanksha Singh, Priyanka Madaan, Dipika Bansal   +2 more
openaire   +2 more sources

Perampanel: A Review in Drug-Resistant Epilepsy

Drugs, 2015
Perampanel (Fycompa®), an orally-active, selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, is a first-in-class antiepileptic drug (AED) offering the convenience of once-daily administration. In the EU and US, perampanel is approved in patients with epilepsy aged ≥12 years for the adjunctive ...
openaire   +2 more sources